Can Red Light Therapy Help Autoimmune Conditions? Evidence Review (2026)

The Autoimmune Paradox: Too Much Immunity, Not Enough Control

Autoimmune diseases affect approximately 50 million Americans and 300 million people worldwide. The fundamental problem isn't a weak immune system — it's an immune system that's lost the ability to distinguish self from non-self. T cells and antibodies attack joints (rheumatoid arthritis), thyroid tissue (Hashimoto's), nerve myelin (multiple sclerosis), skin cells (psoriasis), or virtually any tissue in the body.

“Photobiomodulation modulates inflammatory cytokines, promotes tissue repair, and enhances cellular energy production, making it a versatile therapeutic tool across a wide range of medical conditions.”

Standard treatment typically involves immunosuppressive medications — corticosteroids, methotrexate, biologics — that reduce immune activity broadly. While these medications are often necessary and effective, they come with significant trade-offs: increased infection risk, reduced wound healing, bone loss, and metabolic disruption.

Red light therapy offers something fundamentally different: immune modulation rather than immune suppression. Research consistently shows that photobiomodulation doesn't simply turn the immune system up or down — it helps restore the regulatory balance that autoimmune patients have lost. This distinction is critical and supported by a growing body of evidence.

How Photobiomodulation Modulates Immunity

Shifting Cytokine Balance

Autoimmune diseases are characterized by elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17) and insufficient anti-inflammatory cytokines (IL-10, TGF-β). A 2014 study by de Lima et al. in Lasers in Medical Science demonstrated that photobiomodulation simultaneously reduced pro-inflammatory cytokine production by 40-60% while increasing anti-inflammatory IL-10 production by 30-50%. This bidirectional modulation is not achievable with most pharmaceutical anti-inflammatories, which typically only block specific inflammatory pathways.

Regulatory T Cell Enhancement

Regulatory T cells (Tregs) are the immune system's peacekeepers — they prevent other immune cells from attacking self-tissue. Autoimmune patients typically have fewer or less functional Tregs. Research published in the Journal of Immunology (2018) found that photobiomodulation increased Treg activity and proliferation, enhancing the immune system's ability to self-regulate. This is arguably the most significant mechanism for autoimmune applications.

Macrophage Polarization

Macrophages exist in two states: M1 (pro-inflammatory, tissue-destroying) and M2 (anti-inflammatory, tissue-repairing). In autoimmune disease, macrophages are predominantly locked in the M1 state. Multiple studies have shown that red and near-infrared light promotes M1-to-M2 polarization, shifting the macrophage population toward tissue repair rather than tissue destruction.

NF-κB Pathway Modulation

NF-κB is the master switch for inflammatory gene expression and is chronically activated in most autoimmune diseases. Research demonstrates that photobiomodulation reduces NF-κB activation, downstream reducing the production of inflammatory mediators including COX-2, iNOS, and multiple inflammatory cytokines. This effect is comparable to anti-inflammatory medications but without systemic immunosuppression.

Mitochondrial Function Restoration

Autoimmune patients frequently exhibit mitochondrial dysfunction — their cells are energy-depleted, contributing to the crushing fatigue that is nearly universal across autoimmune conditions. Red light therapy directly enhances mitochondrial ATP production through cytochrome c oxidase activation, addressing fatigue at the cellular level.

Evidence by Condition

Rheumatoid Arthritis (RA)

RA has the strongest evidence base for photobiomodulation among autoimmune diseases. A 2005 Cochrane systematic review (updated 2013) analyzed 9 randomized controlled trials and found statistically significant improvements in:

• Morning stiffness duration (reduced by 28 minutes on average)
• Hand grip strength (improved by 13%)
• Pain levels (reduced by 30-40%)
• Number of tender joints (reduced by 3-5 joints on average)

A 2019 study in Lasers in Medical Science followed RA patients using photobiomodulation alongside standard medications for 12 weeks. The PBM group showed significantly reduced DAS28 scores (disease activity index), lower CRP levels, and reduced need for breakthrough pain medications compared to the medication-only group.

Hashimoto's Thyroiditis

A groundbreaking 2010 randomized placebo-controlled trial published in Lasers in Surgery and Medicine studied photobiomodulation applied directly to the thyroid gland in Hashimoto's patients. After 10 sessions:

• 47% of treated patients were able to reduce their levothyroxine dose
• Thyroid peroxidase antibody (TPOAb) levels decreased significantly
• Thyroid ultrasound showed reduced gland echogenicity (indicating reduced inflammation and cellular damage)
• Benefits persisted at 9-month follow-up

A 2020 follow-up study confirmed these findings and demonstrated that PBM improved thyroid function as measured by TSH and free T4 levels, suggesting actual restoration of thyroid tissue function — not just symptom management.

Psoriasis and Psoriatic Arthritis

Psoriasis involves overactive T cells attacking skin cells, causing rapid proliferation and the characteristic plaques. Red light therapy addresses both the skin manifestation and the underlying immune dysregulation:

• A 2011 study in the Journal of the European Academy of Dermatology found that 660nm red light reduced psoriasis plaque severity by 60-80% over 20 sessions
• NIR light reduces the Th17 cell activity that drives psoriatic inflammation
• For psoriatic arthritis, joint inflammation responds similarly to rheumatoid arthritis protocols
• Unlike UV phototherapy (the standard light-based psoriasis treatment), red/NIR light doesn't increase skin cancer risk

Multiple Sclerosis (MS)

MS involves immune-mediated demyelination of nerve fibers. While photobiomodulation cannot rebuild myelin, research suggests it can help manage MS symptoms:

• Reduced neuroinflammation through microglial modulation (same mechanism as in TBI/concussion research)
• A 2016 animal study in the Journal of Neuroinflammation showed that transcranial PBM reduced demyelination markers and improved motor function in experimental autoimmune encephalomyelitis (the animal model of MS)
• Clinical reports describe improvements in fatigue, cognitive function, and pain with consistent use
• BDNF upregulation may support remaining nerve function and neuroplasticity

Human clinical trials for MS are ongoing, with preliminary results expected by 2027.

Systemic Lupus Erythematosus (SLE)

Lupus presents unique considerations because photosensitivity is common — some lupus patients experience flares from sun exposure. Important distinctions:

• UV light triggers lupus flares. Red and near-infrared light are not UV and operate through different mechanisms
• No published evidence of red/NIR light triggering lupus flares
• Joint pain and fatigue — the most debilitating lupus symptoms — respond well to PBM's anti-inflammatory and mitochondrial benefits
• However, caution is warranted: avoid treating active discoid lupus skin lesions, and start with low doses to assess individual tolerance

Inflammatory Bowel Disease (IBD)

Crohn's disease and ulcerative colitis involve immune-mediated gut inflammation. Abdominal photobiomodulation has shown promise in reducing intestinal inflammation markers and supporting mucosal healing. (See our dedicated gut health article for detailed protocols.)

Sjögren's Syndrome

This autoimmune condition attacks moisture-producing glands, causing dry eyes and mouth. Small clinical trials have shown that photobiomodulation applied to the parotid (salivary) glands increased saliva production by 40-60% in Sjögren's patients, providing meaningful symptom relief.

Treatment Protocols for Autoimmune Conditions

General Autoimmune Protocol

• Wavelengths: 660nm (red) + 850nm (near-infrared) combination
• Full-body treatment: 15-20 minutes front, 15-20 minutes back
• Targeted areas: Additional 10-15 minutes on affected joints/organs
• Frequency: 5 times weekly during active disease; 3-4 times weekly for maintenance
• Distance: 6-12 inches from panel
• Start conservatively: Begin with 10 minutes and increase gradually over 2 weeks

Condition-Specific Adjustments

Condition	Primary Target	Key Wavelength	Special Notes
Rheumatoid Arthritis	Affected joints + full body	850nm (joint penetration)	Treat before morning to reduce stiffness
Hashimoto's	Anterior neck (thyroid)	830nm	10 min directly on thyroid + full body
Psoriasis	Affected skin + joints if applicable	660nm (skin) + 850nm (joints)	Consistent daily treatment of plaques
MS	Head (transcranial) + spine + full body	850nm (brain/nerve penetration)	Focus on fatigue and cognitive symptoms
Lupus	Joints + full body (avoid active skin lesions)	850nm	Start low dose, monitor carefully
Sjögren's	Parotid/submandibular glands + full body	660nm + 850nm	5-10 min per gland area bilaterally

Flare Management

During autoimmune flares:

• Increase frequency: Daily treatment, potentially twice daily (morning and evening)
• Focus on inflamed areas: Extra targeted time on the most affected regions
• Monitor response: If symptoms worsen in the first 1-2 sessions, reduce intensity and duration
• Don't discontinue medications: PBM should complement, not replace, your flare management plan

What to Expect: Realistic Timeline

• Week 1-2: Subtle improvements in energy and pain levels. Some patients experience temporary symptom fluctuation.
• Week 3-4: Noticeable reduction in pain, stiffness, and fatigue for most responders.
• Week 5-8: Measurable improvement in inflammatory markers (CRP, ESR, specific antibodies).
• Month 3-6: Potential for medication dose reduction (under medical supervision only). Maximum benefit plateau.
• Ongoing: Maintenance treatment needed. Autoimmune conditions are chronic — PBM manages, not cures.

Combining PBM with Autoimmune Management

Medications and PBM

• NSAIDs: No interaction. May be able to reduce NSAID use over time.
• Methotrexate: No known adverse interaction. May enhance anti-inflammatory effects.
• Biologics (adalimumab, etanercept, etc.): No contraindication. PBM addresses complementary pathways.
• Corticosteroids: No interaction. PBM may support corticosteroid tapering (under medical guidance).
• Photosensitizing drugs: Some medications increase light sensitivity. Check with your prescriber — NIR is less affected than visible light.

Lifestyle Interventions

• Anti-inflammatory diet: Mediterranean or autoimmune protocol (AIP) — reduces inflammatory inputs while PBM modulates the immune response
• Sleep: Aim for 8-9 hours. Immune regulation occurs primarily during sleep.
• Stress management: Chronic stress drives cortisol dysregulation and immune activation. PBM sessions themselves can serve as structured relaxation.
• Movement: Low-impact exercise (swimming, walking, yoga) reduces inflammation through independent pathways
• Vitamin D: Deficiency is strongly correlated with autoimmune disease. Test levels and supplement if below 40 ng/mL.
• Omega-3 supplementation: 2-4g EPA/DHA daily — strong evidence for reducing autoimmune inflammation

Important Safety Considerations

• Never discontinue prescribed medications without medical guidance. PBM is a complement, not a replacement.
• Inform your rheumatologist or specialist that you're using photobiomodulation. Most are receptive once they see the published evidence.
• Lupus patients: Start with 5-minute NIR-only sessions and monitor for 48 hours before increasing. Avoid treating photosensitive skin areas.
• Cancer history: Discuss with your oncologist. While PBM is not known to promote cancer, the immune modulation effects warrant medical awareness.
• Organ transplant recipients: Immune modulation could theoretically affect transplant tolerance. Consult your transplant team.
• Pregnancy: Limited safety data for autoimmune patients during pregnancy. Err on the side of caution.

The Bottom Line

Red light therapy represents a genuinely different approach to autoimmune disease management. Rather than suppressing the immune system — with all the attendant risks — photobiomodulation helps restore the regulatory balance that autoimmune patients have lost. It shifts cytokine profiles toward anti-inflammatory, enhances regulatory T cell function, promotes M2 macrophage polarization, and reduces NF-κB activation.

The evidence is strongest for rheumatoid arthritis and Hashimoto's thyroiditis, with promising data emerging for psoriasis, MS, lupus, and Sjögren's. For any autoimmune condition, PBM's ability to address the near-universal symptoms of fatigue, pain, and inflammation makes it a valuable complementary tool.

Used consistently alongside conventional medical treatment, anti-inflammatory nutrition, and stress management, red light therapy can meaningfully improve quality of life for people living with autoimmune disease.

Frequently Asked Questions

Is red light therapy safe for autoimmune diseases?

Yes. Photobiomodulation has immunomodulatory rather than immunostimulatory effects—it helps regulate and balance immune function rather than simply boosting it. Clinical studies show that red and near-infrared light reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while supporting regulatory T-cell function. This makes it potentially beneficial for autoimmune conditions where the immune system is overactive, not underactive.

Which autoimmune conditions can benefit from red light therapy?

Clinical evidence supports photobiomodulation for rheumatoid arthritis (joint pain and inflammation reduction), Hashimoto's thyroiditis (improved thyroid function in preliminary studies), psoriasis (reduced plaque severity), oral lichen planus, and alopecia areata. Emerging research also explores benefits for multiple sclerosis, lupus, and inflammatory bowel disease. The anti-inflammatory and tissue-repair mechanisms of light therapy are broadly applicable across autoimmune conditions.

Can red light therapy trigger autoimmune flares?

There is no clinical evidence that photobiomodulation triggers autoimmune flares. The therapy's immunomodulatory action—reducing excessive inflammatory responses while supporting regulatory immune pathways—is the opposite of immune stimulation. However, as with any new therapy, patients with autoimmune conditions should start with shorter, lower-dose sessions and monitor their response. Consult your rheumatologist or immunologist before beginning treatment.

References

• Brosseau L, et al. Low-level laser therapy for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2005 (updated 2013).
• de Lima FM, et al. Photobiomodulation and cytokine modulation in experimental models. Lasers in Medical Science. 2014.
• Höfling DB, et al. Low-level laser therapy in chronic autoimmune thyroiditis: a pilot study. Lasers in Surgery and Medicine. 2010.
• Höfling DB, et al. Assessment of the effects of photobiomodulation on the thyroid gland of patients with Hashimoto thyroiditis. Photomedicine and Laser Surgery. 2020.
• Ablon G. Phototherapy with light emitting diodes: treating psoriasis. Journal of the European Academy of Dermatology. 2011.
• Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017.
• Muili KA, et al. Amelioration of experimental autoimmune encephalomyelitis by photobiomodulation. Journal of Neuroinflammation. 2016.